Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020 to 9.44 million in 2030, at an annual growth rate (AGR) of 1.02%, according to GlobalData, a leading data and analytics company.

Of the 7MM, the diagnosed prevalent cases of CKD in the US are expected to increase at an AGR of 1.59% between 2020 and 2030, followed by Spain (1.51%), and France (1.19%).

The major drivers for the spike in the diagnosed prevalent cases of CKD in the US and the 7MM combined is attributable to the aging population combined with population genetics and other risk factors. Factors such as race, gender, age and family history are highly linked to CKD. Moreover, smoking, obesity, hypertension and diabetes mellitus can also increase the risk for CKD.

PR12882-01.png

Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “CKD is largely an asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time. Currently, there is no cure for CKD; however, treatments can slow the progression of the disease. In the advanced stages of the disease CKD patients are advised to undergo renal replacement therapy (RRT) when the kidneys fail. Another way to reduce the burden of CKD would be early intervention. In order to achieve this, it is important to identify individuals with increased risk for CKD. Determining serum creatinine levels and urinalysis in patients with CKD risk will usually be sufficient for initial screening.”

*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan

Scope

Chronic kidney disease (CKD), or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. In the early stages, CKD is a largely asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time (Centers for Disease Control and Prevention, 2019). As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2019). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered as the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed and total prevalent cases of CKD. The diagnosed and total prevalent cases of CKD are segmented by age (18 years and older), sex, and stage. The diagnosed prevalent cases of CKD are segmented based on dialysis-dependent and non-dialysis-dependent cases. The dialysis dependent cases are further segmented by hemodialysis-dependent and peritoneal dialysis-dependent. Additionally, the diagnosed prevalent cases of CKD were further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases. This epidemiology forecast for CKD is supported by data obtained from peer-reviewed articles and population-based studies:

  • The CKD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies.
  • Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The CKD Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global CKD market.
  • Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for CKD therapeutics in each of the markets covered.
  • Understand magnitude of CKD by stage, hemodialysis-dependent and peritoneal dialysis-dependent; hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases of CKD.

Table of Contents

| About GlobalData

1 CKD – Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CKD – 7MM

2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of CKD

2.4.5 Forecast Assumptions and Methods: Diagnosed and Total Prevalent Cases of CKD by Stage

2.4.6 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence

2.4.7 Diagnosed Prevalent Cases of CKD with Hyperparathyroidism Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases

2.4.8 Diagnosed Prevalent Cases of CKD with Hyperphosphatemia Among Dialysis Dependent and Non-dialysis Dependent CKD Cases

2.4.9 Diagnosed Prevalent Cases of CKD with Diagnosed Prevalent Cases of CKD with Hyperkalemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases

2.5 Epidemiological Forecast for Chronic Kidney Disease Hyperparathyroidism, Hyperphosphatemia and Hyperkalemia (2020-2030)

2.5.1 Diagnosed Prevalent Cases of CKD

2.5.2 Age-Specific Diagnosed Prevalent Cases of CKD

2.5.3 Sex-Specific Diagnosed Prevalent Cases of CKD

2.5.4 Diagnosed Prevalent Cases of CKD by Stage

2.5.5 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence

2.5.6 Diagnosed Prevalent Cases of CKD with Hyperparathyroidism Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases

2.5.7 Diagnosed Prevalent Cases of CKD with Hyperphosphatemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases

2.5.8 Diagnosed Prevalent Cases of CKD With Hyperkalemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases

2.5.9 Total Prevalent Cases of CKD

2.5.10 Age-Specific Total Prevalent Cases of CKD

2.5.11 Sex-Specific Total Prevalent Cases of CKD

2.5.12 Total Prevalent Cases of CKD by Stage

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: KDIGO Classification of CKD

Table 4: Risk Factors and Comorbidities for CKD

Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of CKD, Both Sexes, N, Ages ≥18 Years, 2020 and 2030

Figure 2: 7MM, Total Prevalent Cases of CKD, Both Sexes, N, Ages ≥18 Years, 2020 and 2030

Figure 3: 7MM, Diagnosed Prevalence of CKD, Men and Women, %, Ages ≥18 Years, 2020

Figure 4: 7MM, Total Prevalence of CKD, Men and Women, %, Ages ≥18 Years, 2020

Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD

Figure 6: 7MM, Sources Used to Forecast the Diagnosed and Total Prevalent Cases of CKD by Stage

Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence

Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD with Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases

Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of CKD

Figure 10: 7MM, Diagnosed Prevalent Cases of CKD, N, Both Sexes, Ages ≥18 Years, 2020

Figure 11: 7MM, Diagnosed Prevalent Cases of CKD by Age, N, Both Sexes, 2020

Figure 12: 7MM, Diagnosed Prevalent Cases of CKD by Sex, N, Ages ≥18 Years, 2020

Figure 13: 7MM, Diagnosed Prevalent Cases of CKD by Stage, N, Both Sexes, Ages ≥18 Years, 2020

Figure 14: 7MM, Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence, N, Both Sexes, Ages ≥18 Years, 2020

Figure 15: 7MM, Diagnosed Prevalent Cases of CKD with Hyperparathyroidism, N, Both Sexes, Ages ≥18 Years, 2020

Figure 16: 7MM, Diagnosed Prevalent Cases of CKD With Hyperphosphatemia, N, Both Sexes, Ages ≥18 Years, 2020

Figure 17: 7MM, Diagnosed Prevalent Cases of CKD with Hyperkalemia, N, Both Sexes, ≥18 Years, 2020

Figure 18: 7MM, Total Prevalent Cases of CKD, N, Both Sexes, Ages ≥18 Years, 2020

Figure 19: 7MM, Diagnosed Total Cases of CKD by Age, N, Both Sexes, 2020

Figure 20: 7MM, Total Prevalent Cases of CKD by Sex, N, Ages ≥18 Years, 2020

Figure 21: 7MM, Total Prevalent Cases of CKD by Stage, N, Both Sexes, Ages ≥18 Years, 2020

Frequently asked questions

Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030 in real time.

  • Access a live Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.